<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23447805</article-id><article-id pub-id-type="pmc">3581801</article-id><article-id pub-id-type="doi">10.3389/fonc.2013.00037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Editorial Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Anti-idiotype antibodies in cancer treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gomez</surname><given-names>Daniel E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>V&#x000e1;zquez</surname><given-names>Ana M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alonso</surname><given-names>Daniel F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mac&#x000ed;as</surname><given-names>Amparo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Science and Technology, Universidad Nacional de Quilmes</institution><country>Buenos Aires, Argentina</country></aff><aff id="aff2"><sup>2</sup><institution>Centro de Inmunologia Molecular</institution><country>La Havana, Cuba</country></aff><author-notes><corresp id="fn001">*Correspondence: <email xlink:type="simple">degomez@unq.edu.ar</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Tumor Immunity, a specialty of Frontiers in Oncology.</p></fn><fn fn-type="edited-by"><p>Edited by: Wolf Herv&#x000e9; Fridman, INSERM, University Paris Descartes, France</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="collection"><year>2013</year></pub-date><volume>3</volume><elocation-id>37</elocation-id><history><date date-type="received"><day>01</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Gomez, V&#x000e1;zquez, Alonso and Mac&#x000ed;as.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</license-p></license></permissions><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="11"/><page-count count="1"/><word-count count="882"/></counts></article-meta></front><body><p>Anti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopes that are located in the variable region, including the antigen binding site, of another antibody. When the last is the case, these anti-Id Abs can act as surrogates of the original antigen. The capability of anti-Id Abs to modulate the immune response has been the basis for the development of anti-Id vaccines against different antigens, including tumor-associated antigens. Over the years, its use in cancer has been demonstrated as effective and promising. This book &#x0201c;Anti-idiotype antibodies in cancer treatment&#x0201d; resumes the latest findings in the field. The book starts with an opinion article by Gomez et al. (<xref ref-type="bibr" rid="B2">2012</xref>), whereas the authors discuss a method for prioritization of cancer antigens that paves the way to take more rational, informed decisions in vaccine development. Following, we will find a number of reviews that conform a complete updating on the subject. The first one by Kieber-Emmons et al. (<xref ref-type="bibr" rid="B4">2012</xref>) explore the concept of anti-Id Abs with its achievements and drawbacks. Following, Ladjemi (<xref ref-type="bibr" rid="B5">2012</xref>) focuses on recent achievements of use of anti-Id Abs as cancer vaccines in solid tumors. L&#x000f3;pez-Requena et al. (<xref ref-type="bibr" rid="B7">2012</xref>) focus on the role of anti-Id vaccination in cancer management and on the current developments used to foster anti-idiotypic B and T cell responses. V&#x000e1;zquez et al. (<xref ref-type="bibr" rid="B10">2012a</xref>,<xref ref-type="bibr" rid="B11">b</xref>) deeply analyze the immunological mechanisms involved in the use of these antibodies, while V&#x000e1;zquez et al. (<xref ref-type="bibr" rid="B10">2012a</xref>,<xref ref-type="bibr" rid="B11">b</xref>) focus on racotumomab, an anti-Id vaccine already in Phase III clinical trials. Finally, Fredriksen et al. (<xref ref-type="bibr" rid="B1">2012</xref>) present a hypothetical model for how the APC-targeted vaccine molecules enhance Id-specific T and B cells. Next, the original article of Segatori et al. (<xref ref-type="bibr" rid="B9">2012</xref>) conveys preclinical research on racotumomab with or without chemotherapy, and explores the biological role of N-glycolyl gangiosides in a lung cancer mouse model. Two interesting clinical case studies are also part of this book. First, Llanos et al. (<xref ref-type="bibr" rid="B6">2012</xref>) report a maintenance treatment with chemotherapy and immunotherapy in a patient with non-small cell lung cancer. Also, Sampor et al. (<xref ref-type="bibr" rid="B8">2012</xref>) present results about the immune response to racotumomab in a child with relapsed neuroblastoma. The book closes with a very interesting article by G&#x000f3;mez and Ardigo (<xref ref-type="bibr" rid="B3">2012</xref>), analyzing the pharmaceutical perspective of the development of anti-Id Abs in cancer treatment, with a fresh point of view about the relationship between academy and industry. We as editors were very happy to work with such an excellent group of authors, putting together a book with good quality articles that shed light to the use of anti-Id Abs in cancer. Likewise, we hope it constitutes to the reader interesting material for their fields.</p></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksen</surname><given-names>A. B.</given-names></name><name><surname>Sandlie</surname><given-names>I.</given-names></name><name><surname>Bogen</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>154</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00154</pub-id><pub-id pub-id-type="pmid">23115759</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>D. E.</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>A. M.</given-names></name><name><surname>Alonso</surname><given-names>D. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>66</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00066</pub-id><pub-id pub-id-type="pmid">22754871</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez</surname><given-names>R. E.</given-names></name><name><surname>Ardigo</surname><given-names>M. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>147</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00147</pub-id><pub-id pub-id-type="pmid">23112955</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieber-Emmons</surname><given-names>T.</given-names></name><name><surname>Monzavi-Karbassi</surname><given-names>B.</given-names></name><name><surname>Pashov</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Murali</surname><given-names>R.</given-names></name><name><surname>Kohler</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>The promise of the anti-idiotype concept</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>196</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00196</pub-id><pub-id pub-id-type="pmid">23267437</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladjemi</surname><given-names>M. Z.</given-names></name></person-group> (<year>2012</year>). <article-title>Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>158</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00158</pub-id><pub-id pub-id-type="pmid">23133825</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llanos</surname><given-names>A.</given-names></name><name><surname>Savignano</surname><given-names>M.</given-names></name><name><surname>Cinat</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>152</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00152</pub-id><pub-id pub-id-type="pmid">23112957</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Requena</surname><given-names>A.</given-names></name><name><surname>Burrone</surname><given-names>O. R.</given-names></name><name><surname>Cesco-Gaspere</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>159</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00159</pub-id><pub-id pub-id-type="pmid">23162790</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampor</surname><given-names>C.</given-names></name><name><surname>Guthmann</surname><given-names>M. D.</given-names></name><name><surname>Scursoni</surname><given-names>A.</given-names></name><name><surname>Cacciavillano</surname><given-names>W.</given-names></name><name><surname>Torbidoni</surname><given-names>A.</given-names></name><name><surname>Galluzzo</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Immune response to racotumomab in a child with relapsed neuroblastoma</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>195</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00195</pub-id><pub-id pub-id-type="pmid">23267436</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segatori</surname><given-names>V. I.</given-names></name><name><surname>Vazquez</surname><given-names>A. M.</given-names></name><name><surname>Gomez</surname><given-names>D. E.</given-names></name><name><surname>Gabri</surname><given-names>M. R.</given-names></name><name><surname>Alonso</surname><given-names>D. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>160</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00160</pub-id><pub-id pub-id-type="pmid">23162791</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e1;zquez</surname><given-names>A. M.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>A. M.</given-names></name><name><surname>Mac&#x000ed;as</surname><given-names>A.</given-names></name><name><surname>Montero</surname><given-names>E.</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>D. E.</given-names></name><name><surname>Alonso</surname><given-names>D. F.</given-names></name><etal/></person-group> (<year>2012a</year>). <article-title>Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides &#x02013; preclinical and clinical data</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>150</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00150</pub-id><pub-id pub-id-type="pmid">23110257</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e1;zquez</surname><given-names>A. M. H.</given-names></name><name><surname>Rodr&#x000ed;guez-Zhurbenko</surname><given-names>N.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>A. M. V.</given-names></name></person-group> (<year>2012b</year>). <article-title>Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>170</issue>
<pub-id pub-id-type="doi">10.3389/fonc.2012.00170</pub-id><pub-id pub-id-type="pmid">23181219</pub-id></mixed-citation></ref></ref-list></back></article>